Generic Name and Formulations:
Fluorometholone 0.1%; oph susp; contains benzalkonium chloride.
Indications for FML:
Adults and Children:
<2yrs: not recommended. ≥2yrs: 1 drop 2–4 times daily or small amount of ointment 1–3 times daily. May give every 4 hours for 1st 24–48 hrs. Reevaluate after 2 days.
Fungal, mycobacterial, viral (except herpes zoster), or untreated bacterial infections.
Corneal or scleral thinning. Glaucoma. Monitor for secondary infections and intraocular pressure in prolonged use. Avoid abrupt cessation. May mask or exacerbate infections. Pregnancy (Cat.C). Nursing mothers: not recommended.
Ocular irritation, increased intraocular pressure with possible glaucoma, infrequent optic nerve damage, cataracts, delayed wound healing; systemic hypercorticoidism (rare).
Susp—5mL, 10mL, 15mL; Oint—3.5g; Forte—5mL, 10mL, 15mL
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|